Hidden fungal threat in COVID-19 ICU patients revealed

NCT ID NCT04818853

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study monitored 219 adults with severe COVID-19 who needed a ventilator for at least 72 hours. Researchers checked for serious fungal infections, especially aspergillosis, using standard diagnostic methods. The goal was to learn how common these infections are and what puts patients at risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors better detect and prevent dangerous fungal infections in severely ill COVID-19 patients.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly improve patient outcomes. Results may not apply to all COVID-19 patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aspergillosis COVID-19 fungal infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States